These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31648650)

  • 1. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
    Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
    Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tankyrases as drug targets.
    Lehtiö L; Chi NW; Krauss S
    FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.
    Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L
    PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc binding catalytic domain of human tankyrase 1.
    Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
    J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening and structural analysis of flavones inhibiting tankyrases.
    Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
    J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tankyrase inhibitors as therapeutic targets for cancer.
    Kamal A; Riyaz S; Srivastava AK; Rahim A
    Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
    Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
    Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
    Riffell JL; Lord CJ; Ashworth A
    Nat Rev Drug Discov; 2012 Dec; 11(12):923-36. PubMed ID: 23197039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
    Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
    Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
    ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
    Lakshmi TV; Bale S; Khurana A; Godugu C
    Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
    Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
    J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
    Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
    Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
    Mariotti L; Pollock K; Guettler S
    Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.